Bolt Biotherapeutics Q1 EPS $(0.29) Beats $(0.36) Estimate, Sales $1.22M Beat $767.50K Estimate

Author: Benzinga Newsdesk | May 12, 2025 03:31pm
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.36) by 19.44 percent. This is a 3.57 percent decrease over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $1.22 million which beat the analyst consensus estimate of $767.50 thousand by 59.22 percent. This is a 76.83 percent decrease over sales of $5.27 million the same period last year.

Posted In: BOLT